File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Use of the hepatitis B recombinant DNA yeast vaccine (H-B-VAX II) in children: Two doses vs. three doses of 5 μg regime; an interim report

TitleUse of the hepatitis B recombinant DNA yeast vaccine (H-B-VAX II) in children: Two doses vs. three doses of 5 μg regime; an interim report
Authors
Issue Date1986
PublisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/jinf
Citation
Journal Of Infection, 1986, v. 13 SUPPL. A, p. 19-25 How to Cite?
AbstractIn a prospective randomised trial, children of hepatitis B carriers who were 3 months to 11 years of age and negative for all hepatitis B viral markers were randomised to receive (a) two doses of 5μg of hepatitis B recombinant DNA yeast vaccine (H-B-VAX II) at 0 and 1 month (Group I), (b) three doses of 5 μg of H-B-VAX II at 0, 1 and 6 months (Group II) and (c) three doses of 10 μg of plasma-derived hepatitis B vaccine (H-B-VAX) (Group III). In the 141 children receiving H-B-VAX II, i.e. in Group I and Group II, side-effects were few and transient. Fever occurred in 10% of the vaccinees. Anti-HBs response rate was 96-100% by 8 months. None of the vaccinees became positive for anti-HBc. The geometric mean of the anti-HBs titre at 8 months was higher for Group II than for Group I (P < 0·001). The practical and theoretical necessity for this higher titre of anti-HBs in the prevention of future infection by the hepatitis B virus is discussed. Both the two-dose regime and the three-dose regime of 5 μg of H-B-VAX II were safe, effective and immunogenic in children. © 1986 The British Society for the Study of Infection.
Persistent Identifierhttp://hdl.handle.net/10722/161710
ISSN
2015 Impact Factor: 4.382
2015 SCImago Journal Rankings: 2.070
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLai, CLen_US
dc.contributor.authorYeoh, EKen_US
dc.contributor.authorChang, WKen_US
dc.contributor.authorLo, VWLen_US
dc.contributor.authorNg, LNKen_US
dc.date.accessioned2012-09-05T05:14:14Z-
dc.date.available2012-09-05T05:14:14Z-
dc.date.issued1986en_US
dc.identifier.citationJournal Of Infection, 1986, v. 13 SUPPL. A, p. 19-25en_US
dc.identifier.issn0163-4453en_US
dc.identifier.urihttp://hdl.handle.net/10722/161710-
dc.description.abstractIn a prospective randomised trial, children of hepatitis B carriers who were 3 months to 11 years of age and negative for all hepatitis B viral markers were randomised to receive (a) two doses of 5μg of hepatitis B recombinant DNA yeast vaccine (H-B-VAX II) at 0 and 1 month (Group I), (b) three doses of 5 μg of H-B-VAX II at 0, 1 and 6 months (Group II) and (c) three doses of 10 μg of plasma-derived hepatitis B vaccine (H-B-VAX) (Group III). In the 141 children receiving H-B-VAX II, i.e. in Group I and Group II, side-effects were few and transient. Fever occurred in 10% of the vaccinees. Anti-HBs response rate was 96-100% by 8 months. None of the vaccinees became positive for anti-HBc. The geometric mean of the anti-HBs titre at 8 months was higher for Group II than for Group I (P < 0·001). The practical and theoretical necessity for this higher titre of anti-HBs in the prevention of future infection by the hepatitis B virus is discussed. Both the two-dose regime and the three-dose regime of 5 μg of H-B-VAX II were safe, effective and immunogenic in children. © 1986 The British Society for the Study of Infection.en_US
dc.languageengen_US
dc.publisherWB Saunders Co Ltd. The Journal's web site is located at http://www.elsevier.com/locate/jinfen_US
dc.relation.ispartofJournal of Infectionen_US
dc.subject.meshChilden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshClinical Trials As Topicen_US
dc.subject.meshDose-Response Relationship, Immunologicen_US
dc.subject.meshFemaleen_US
dc.subject.meshHepatitis B - Prevention & Controlen_US
dc.subject.meshHepatitis B Antibodies - Analysisen_US
dc.subject.meshHepatitis B Surface Antigens - Analysisen_US
dc.subject.meshHepatitis B Vaccinesen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunization Scheduleen_US
dc.subject.meshInfanten_US
dc.subject.meshMaleen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRandom Allocationen_US
dc.subject.meshViral Hepatitis Vaccines - Administration & Dosage - Adverse Effects - Immunologyen_US
dc.titleUse of the hepatitis B recombinant DNA yeast vaccine (H-B-VAX II) in children: Two doses vs. three doses of 5 μg regime; an interim reporten_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0163-4453(86)92623-X-
dc.identifier.pmid2943812en_US
dc.identifier.scopuseid_2-s2.0-0022743552en_US
dc.identifier.volume13en_US
dc.identifier.issueSUPPL. Aen_US
dc.identifier.spage19en_US
dc.identifier.epage25en_US
dc.identifier.isiWOS:A1986D331500006-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridYeoh, EK=35427828500en_US
dc.identifier.scopusauthoridChang, WK=37043471800en_US
dc.identifier.scopusauthoridLo, VWL=7005645861en_US
dc.identifier.scopusauthoridNg, LNK=7201477909en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats